2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What External and Internal Drivers Are Contributing to the Growth of theGlaucoma Market?

The increasing incidence of chronic eye disorders is predicted to significantly drive expansion in the glaucoma market. These are long-standing eye-related health issues that frequently result in constant visual impairment or discomfort, necessitating continuous care and intervention. Factors such as the aging population, more screen exposure, lifestyle habits, and higher incidence rates of diseases such as diabetes and hypertension are resulting in a surge in these chronic eye conditions. Glaucoma treatment plays a vital role in such conditions to reduce intraocular pressure, halt additional optic nerve harm, and maintain vision, as untreated glaucoma can result in irreversible blindness. For example, as per the UK-based National Health Service (NHS) in December 2024, over 2 million people in the UK were living with vision loss in 2024. Moreover, these figures are estimated to rise by 27%, approximately reaching 2.8 million by 2035. Thus, the escalating incidence of chronic eye disorders is fueling the growth of the glaucoma market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20820&type=smp

#What is the Anticipated CAGR of theGlaucoma Market, and What Factors Will Drive It?

The market size of glaucoma has shown significant growth in the past few years. The market which currently stands at $7.76 billion in 2024, is projected to increase to $8.22 billion in 2025, growing at a compound annual growth rate (CAGR) of 5.9%. The hefty growth observed in the historical period is a result of the rising awareness regarding eye health, increased spending on healthcare, a surge in the use of telemedicine for eye care services, expansion of healthcare infrastructure, and the implementation of numerous government healthcare campaigns.

The size of the glaucoma market is predicted to experience significant expansion in the upcoming years. The projected growth will see the market reach $10.20 billion by 2029, with a compound annual growth rate (CAGR) standing at 5.5%. Factors contributing to the anticipated growth during this forecast period include a growing older population, an increased incidence of glaucoma, an escalating demand for procedures that are minimally invasive, a heightened prevalence of diabetes and hypertension. Dominant trends expected during the forecast period encompass advancements in diagnostic technologies, the introduction of novel drug treatments, technological improvements in surgical equipment, the presence of combination therapies, and the advent of robotic surgeries.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20820

Which Upcoming Market Trends and Innovations Are Set to Influence theGlaucoma Market’s Path Forward?

Leading businesses in the glaucoma market are concentrating on creating pioneering treatments, including Rho-kinase (ROCK) inhibitors, which provide a dual function by reducing intraocular pressure via the augmentation of aqueous humour outflow and the relaxation of trabecular meshwork cells. This enriches their effectiveness in managing glaucoma. ROCK inhibitors are a group of medications that obstruct the function of Rho-kinase enzymes, enabling them to govern cell contraction and aid in the treatment of glaucoma by decreasing intraocular pressure. For example, in July 2023, Santen Pharmaceutical Co. Ltd., a Japanese eye care product firm, introduced Roclanda in the UK. Roclanda, a fixed-dose combination (FDC) of latanoprost and netarsudil (a unique ROCK inhibitor), efficiently diminishes intraocular pressure by treating trabecular meshwork dysfunction. It is recommended for adult patients diagnosed with primary open-angle glaucoma or ocular hypertension who haven’t achieved sufficient IOP reduction with the single therapy use of a prostaglandin or netarsudil. The emergence of Roclanda in Europe signifies the first new category of glaucoma treatment in the past 25 years, introducing a significant advancement in therapy. Roclanda harmonizes netarsudil and latanoprost, heightening the outflow via conventional (trabecular) and unconventional (uveoscleral) pathways, thereby offering a holistic approach to treating elevated IOP.

Who Are the Dominant Market Players Pushing the Boundaries of theGlaucoma Market?

Major companies operating in the glaucoma market are Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Limited, Bausch & Lomb Corp., Carl Zeiss Meditec, Santen Pharmaceuticals Co. Ltd., Topcon Corporation, Thea Laboratoires, Corza Ophthalmology, Lumenis Ltd., Alcon Inc., Viva BioInnovator, Glaukos Corporation, Iridex Corporation, Nova Eye Medical Ltd., Renova Life Sciences Private Limited, Qlaris Bio Inc., PolyActiva Pty Ltd., Nidek Co. Ltd., Haag-Streit AG

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/glaucoma-global-market-report

What Are the Core Segments of the Glaucoma Market, and How Do They Contribute to Growth?

The glaucoma market covered in this report is segmented –

1) By Disease Type: Open Angle Glaucoma, Angle Closure Glaucoma, Other Disease Types

2) By Diagnosis: Tonometry, Ophthalmoscopy, Perimetry, Gonioscopy

3) By Drug Class: Beta Blockers, Prostaglandins, Alpha Adrenergic Agonist, Carbonic Anhydrase Inhibitors, Combination Drugs, Other Drug Classes

4) By Administration: Oral, Injections, Intravitreal, Other Administrations

5) By End-User: Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Open Angle Glaucoma: Primary Open Angle Glaucoma (POAG), Secondary Open Angle Glaucoma

2) By Angle Closure Glaucoma: Primary Angle Closure Glaucoma, Secondary Angle Closure Glaucoma

3) By Other Disease Types: Normal-Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma, Congenital Glaucoma

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=20820&type=smp

What Regions Are Dominating the Glaucoma Market Growth?

North America was the largest region in the glaucoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glaucoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Glaucoma Market 2025, By The Business Research Company:

Antiglaucoma Drugs Opportunities And Strategies Global Market Report 2025

https://thebusinessresearchcompany.com/report/antiglaucoma-drugs-market

Antiglaucoma Drugs Global Market Report 2025

https://thebusinessresearchcompany.com/report/antiglaucoma-drugs-global-market-report

Glaucoma Surgery Devices Global Global Market Report 2025

https://thebusinessresearchcompany.com/report/glaucoma-surgery-devices-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: